medtech

New US hospital and surgical reimbursement rates for 2026 are rising faster than inflation, bolstering the earnings outlook for the sector.

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term patient investors.

In a sector where utilisation and reimbursement are tightly linked, reduction in admin drag supports more stable, visible revenue streams.

The Continuous Glucose Monitor market is poised for structural growth, and we believe Dexcom is best positioned to dominate the growth cycle

This commercial med-tech is valued at just ~A$40m despite having innovative tech, market adoption and a partnership with a global giant.

ResMed (ASX:RMD) reported its June quarter and full year results after the U.S. market closed on Friday morning. The company met consensus expectations for both...

Don't sleep on this alternative treatment to CPAP in the massive and growing obstructive sleep apnea market

The medtech landscape is rife with fast growing companies typically operating in oligopolistic industry structures that drive profitability.

On Wednesday 23 August, Curvebeam AI (ASX: CVB) was listed on the ASX. The market for this kind of company remains hostile: biotech indices are close to their lows and...

During a once-in-a-century global pandemic perhaps counterintuitively one of the most affected sectors was the medical device manufacturers. Weighed down by...